 |
 |
 |
 |
 |
 |
News from SGC
Posted on Thursday 27th of August 2015
Posted on Friday 17th of July 2015
Professors Markus Perkmann from Imperial College London and Henri Schildt of Aalto University School of Business report on their findings in the journal Research Policy on managing open data partnerships and the role of boundary organizations such as the SGC.
Open data partnerships between firms and universities: The role of boundary organizations
Markus Perkmanna & Henri Schildt
Research Policy Volume 44, Issue 5, June 2015, Pages 1133–1143
Posted on Thursday 16th of July 2015
WD Repeat domain 5 (WDR5) is a critical part of the human trithorax/COMPASS complexes which are responsible for methylation of lysine 4 on histone 3 (H3K4) via one of several catalytic subunits, Mixed-Lineage Leukemia (MLL), MLL2, MLL3, or MLL4 proteins. Early hypotheses that antagonism of the MLL-WDR5 interaction might lead to reduction of H3K4 methylation encouraged us to search for small-molecule inhibitors of this interaction (PubMed 22989411). More recently, through a collaboration with the Ontario Institute for Cancer Research (OICR) we developed the chemical probe, OICR-9429, a potent, selective, and cell-penetrant WDR5 antagonist. Treatment of normal cells with OICR-9429 indicates... more
Posted on Friday 10th of July 2015
Bromo and extra-terminal (BET) proteins tether the transcriptional machinery to chromatin, stimulating programmes that are often hijacked in disease.
Posted on Friday 12th of June 2015
In their most recent issue of Show me the Evidence, the Canadian Institutes for Health Research (CIHR) included a feature piece on SGG's research in an interview with SGC-Toronto's Chief Scientist, Dr Cheryl Arrowsmith.
Posted on Monday 25th of May 2015
Pharmaceutical companies who are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) join forces with small and medium-sized enterprise (SMEs) as well as universities and hospitals in an Innovative Medicines Initiative (IMI) supported public private partnership, ULTRA-DD. In this project, we aim to define and validate new drug targets in inflammatory and auto-immune diseases by testing high quality chemical probes and antibodies in patient-cell derived assays to facilitate a greater understanding of disease pathology.
Posted on Wednesday 13th of May 2015
Recent article on Nature Biotechnology highlights SGC’s new open access initiative to use human cell for target validation.
Link: http://www.nature.com/nbt/journal/v33/n5/full/nbt0515-436.html?WT.ec_id=NBT-201505
Posted on Wednesday 13th of May 2015
Chas Bountra, SGC Oxford’s Chief Scientist and Professor of Translational Medicine at the University of Oxford, is a guest on Will Gompertz’s BBC radio show to discuss how SGC and Oxford scientists are contributing to the development of new and affordable medicines for diseases such as dementia.
http://www.bbc.co.uk/programmes/p02q9w8w (interview starts at 1:08:52)
Posted on Friday 17th of April 2015
Toronto, ON (April 17th, 2015) - The Structural Genomics Consortium (SGC) at the University of Toronto and the Ontario Brain Institute (OBI) have entered into an “open-source” research partnership with two Toronto-based hospitals to test tool compounds, called chemical probes, against epigenetic proteins in research models of Rett syndrome.
Pages
